Fig. 4.

MST1r has a prognostic value and correlates with p53 status in human pancreatic cancer. (A) Oncoprint plot reports TP53 and MST1r mutational status in a meta‐analysis of 5 PDAC patient data sets (including QCMG, TCGA and ICGC). N = 960. Source cbioportal.org. (B) Expression level of MST1r in p53 mutant (missense or deletion) and p53 wt cohorts of PDAC patients from TCGA data set. (C) Expression level of MST1r in different subtypes of PDAC. (D) Overall survival of MST1r high/low cohorts of patients from TCGA data set. (E) Chromatin accessibility on MST1r genomic site (ATAC‐seq) of PDAC patients (GSE124229) stratified for the recurrence status. (F,G) Quantification of peak width in PDAC patients with recurrence (R) and no recurrence (N‐R). All peaks are reported in (F); peaks 1, 2 and 3 are reported individually in (G). The illustrated data (B, C, F and G) report a dot for each individual patient ± SEM. The P‐value was calculated using the one‐way ANOVA test (B,C) (*P < 0.05 and ****P < 0.0001) or the t‐test (F,G).